Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response

Folia Histochemica et Cytobiologica

Volumn 45, Issue 4, 2007, Pages 349-355

  Rossowska, Joanna ^a   Pajtasz Piasecka, Elzbieta ^a   Szyda, Anna ^a   Zietara, Natalia ^a   Duś, Danuta ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

DC migration; IFN production; Mouse colon carcinoma MC38; T cell cytotoxicity; Tumor antigen loaded dendritic cells

Indexed keywords

DENDRITIC CELL VACCINE; ENHANCED GREEN FLUORESCENT PROTEIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CELL ISOLATION; CELL MIGRATION; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EX VIVO STUDY; FEMALE; GENETIC TRANSDUCTION; IMMUNOHISTOLOGY; LYMPH NODE; MOUSE; NONHUMAN; SPLEEN; TISSUE DISTRIBUTION;

MUS;

EID: 38849173687     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Banchereau J, Briere F, Caux C, et al. Immunology of dendritic cells. Ann Rev Immunol. 2000;18:767-811.
2. Flores-Romo L. In vitro maturation and migration of dendritic cells. Immunology. 2001;102:255-262.
3. Byrne S, Halliday G. Dendritic cells: making progress with tumor regression? Immunology & Cell Biology. 2002;80:520-530.
4. Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8 T cell precursors. J Immunol. 2004;172:4215-4224.
5. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 1996;183:317-322.
6. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with syngeneic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1996;1:1297-1302.
7. Iwashita Y, Tahara K, Goto S. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother. 2003;52:155-161.
8. Pajtasz-Piasecka E, Szyda A, Rossowska J, et al. Loss of tumorigenicity of murine colon adenocarcinoma MC38/0 cell line after transduction with retroviral vectors carrying murine IL-12 genes. Folia Biologica (Praha). 2004;50:7-14.
9. Chang JW, Peng M, Vaquerano JE, et al. Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies. Anticancer Res. 2000;20:1329-36.
10. Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer. 2001;93:539-48.
11. Lappin MB, Weiss JM, Delattre V, et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology. 1999;98:181-188.
12. Martin-Fontecha A, Sebastiani S, Hopken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med. 2003;198:615-621.
13. Mullins DW, Engelhard VH. Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. J Immunol. 2006;176: 4535-42.
14. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother. 2001;24:392-407.
15. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264: 961-965.
16. Yewdell JW, Norbury CC, Bennink JR. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8 T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol. 1999;73:1-77.